Table 2. Clinicopathological analysis of hemopexin expression in 163 patients diagnosed with invasive PDAC who had received no neoadjuvant therapy.
| Variable | Hemopexin- group (n = 26) | Hemopexin+ group (n = 137) | p value | |
|---|---|---|---|---|
| Age | Median | 66 (27–82) | 68 (33–88) | 0.1366 |
| Sex | Male | 16 (62%) | 87 (64%) | 0.8489 |
| Female | 10 (38%) | 50 (36%) | ||
| Location | Head | 23 (88%) | 80 (59%) | 0.0132 |
| Body | 2 (8%) | 47 (34%) | ||
| Whole | 1 (4%) | 10 (7%) | ||
| Size (mm) | Mean±SD | 31±10.3 | 31±11.6 | 0.7925 |
| R status | R0 | 23 (88%) | 122 (89%) | 0.0796 |
| R1 | 1 (4%) | 14 (10%) | ||
| R2 | 2 (8%) | 1 (1%) | ||
| T stage | ≤2 | 19 (73%) | 104 (76%) | 0.7581 |
| ≥3 | 7 (27%) | 33 (24%) | ||
| N stage | ≤1 | 24 (92%) | 101 (74%) | 0.0399 |
| 2 | 2 (8%) | 36 (26%) | ||
| M stage | 0 | 22 (85%) | 112 (82%) | 0.7263 |
| 1 | 4 (15%) | 25 (18%) | ||
| LN ratio | Mean±SD | 0.05±0.04 | 0.12±0.15 | 0.0252 |
| Histological grade | G1 | 4 (15%) | 25 (18%) | 0.6250 |
| G2 | 21 (81%) | 100 (73%) | ||
| G3 | 1 (4%) | 12 (9%) | ||
| Venous invasion | ≤2 | 20 (77%) | 67 (50%) | 0.0096 |
| 3 | 6 (23%) | 69 (50%) | ||
| Lymphatic invasion | ≤2 | 25 (96%) | 105 (77%) | 0.0232 |
| 3 | 1 (4%) | 32 (23%) | ||
| Nerve invasion | ≤2 | 16 (62%) | 69 (50%) | 0.2957 |
| 3 | 10 (38%) | 68 (50%) |
TNM classification was based on UICC 8th edition. Tumor-invasion grade was based on the Classification of Pancreatic Carcinoma, 4th English edition, by Japan Pancreas Society. The degrees of venous invasion (v), lymphatic invasion (ly), and nerve invasion (ne) were classified into four grades (0: negative; 1: minor; 2: moderate; 3: severe) according to pathologists’ assessment.
LN, lymph node; PDAC, pancreatic ductal adenocarcinoma.